Martin Bauer1, Rudolf Karch2, Beatrix Wulkersdorfer3, Cécile Philippe4, Lukas Nics4, Eva-Maria Klebermass4, Maria Weber3, Stefan Poschner5, Helmuth Haslacher6, Walter Jäger5, Nicolas Tournier7, Wolfgang Wadsak4,8, Marcus Hacker4, Markus Zeitlinger3, Oliver Langer3,4,9. 1. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria martin.m.bauer@meduniwien.ac.at. 2. Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria. 3. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. 4. Division of Nuclear Medicine, Department of Biomedical Imaging und Image-Guided Therapy, Medical University of Vienna, Vienna, Austria. 5. Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria. 6. Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria. 7. IMIV, CEA, INSERM, CNRS, Université Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France. 8. Center for Biomarker Research in Medicine, CBmed GmbH, Graz, Austria; and. 9. Center for Health and Bioresources, Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Abstract
The adenosine triphosphate-binding cassette transporters P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) are 2 efflux transporters at the blood-brain barrier (BBB) that effectively restrict brain distribution of dual ABCB1/ABCG2 substrate drugs, such as tyrosine kinase inhibitors. Pharmacologic inhibition of ABCB1/ABCG2 may improve the efficacy of dual-substrate drugs for treatment of brain tumors, but no marketed ABCB1/ABCG2 inhibitors are currently available. In the present study, we examined the potential of supratherapeutic-dose oral erlotinib to inhibit ABCB1/ABCG2 activity at the human BBB. Methods: Healthy men underwent 2 consecutive PET scans with 11C-erlotinib: a baseline scan and a second scan either with concurrent intravenous infusion of the ABCB1 inhibitor tariquidar (3.75 mg/min, n = 5) or after oral intake of single ascending doses of erlotinib (300 mg, n = 7; 650 mg, n = 8; or 1,000 mg, n = 2). Results: Although tariquidar administration had no effect on 11C-erlotinib brain distribution, oral erlotinib led, at the 650-mg dose, to significant increases in volume of distribution (23% ± 13%, P = 0.008), influx rate constant of radioactivity from plasma into brain (58% ± 26%, P = 0.008), and area under the brain time-activity curve (78% ± 17%, P = 0.008), presumably because of combined partial saturation of ABCG2 and ABCB1 activity. Inclusion of further subjects into the 1,000-mg dose group was precluded by adverse skin events (rash). Conclusion: Supratherapeutic-dose erlotinib may be used to enhance brain delivery of ABCB1/ABCG2 substrate anticancer drugs, but its clinical applicability for continuous ABCB1/ABCG2 inhibition at the BBB may be limited by safety concerns.
The adenosine triphosphate-binding cassette transporters P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) are 2 efflux transporters at the blood-brain barrier (BBB) that effectively restrict brain distribution of dual ABCB1/ABCG2 substrate drugs, such as tyrosine kinase inhibitors. Pharmacologic inhibition of ABCB1/ABCG2 may improve the efficacy of dual-substrate drugs for treatment of brain tumors, but no marketed ABCB1/ABCG2 inhibitors are currently available. In the present study, we examined the potential of supratherapeutic-dose oral erlotinib to inhibit ABCB1/ABCG2 activity at the human BBB. Methods: Healthy men underwent 2 consecutive PET scans with 11C-erlotinib: a baseline scan and a second scan either with concurrent intravenous infusion of the ABCB1 inhibitor tariquidar (3.75 mg/min, n = 5) or after oral intake of single ascending doses of erlotinib (300 mg, n = 7; 650 mg, n = 8; or 1,000 mg, n = 2). Results: Although tariquidar administration had no effect on 11C-erlotinib brain distribution, oral erlotinib led, at the 650-mg dose, to significant increases in volume of distribution (23% ± 13%, P = 0.008), influx rate constant of radioactivity from plasma into brain (58% ± 26%, P = 0.008), and area under the brain time-activity curve (78% ± 17%, P = 0.008), presumably because of combined partial saturation of ABCG2 and ABCB1 activity. Inclusion of further subjects into the 1,000-mg dose group was precluded by adverse skin events (rash). Conclusion: Supratherapeutic-dose erlotinib may be used to enhance brain delivery of ABCB1/ABCG2 substrate anticancer drugs, but its clinical applicability for continuous ABCB1/ABCG2 inhibition at the BBB may be limited by safety concerns.
Authors: Nicolas Tournier; Sebastien Goutal; Severin Mairinger; Irene Hernández-Lozano; Thomas Filip; Michael Sauberer; Fabien Caillé; Louise Breuil; Johann Stanek; Anna F Freeman; Gaia Novarino; Charles Truillet; Thomas Wanek; Oliver Langer Journal: J Cereb Blood Flow Metab Date: 2020-10-20 Impact factor: 6.200
Authors: Antonia Högnäsbacka; Alex J Poot; Danielle J Vugts; Guus A M S van Dongen; Albert D Windhorst Journal: Pharmaceuticals (Basel) Date: 2022-04-05
Authors: Kathryn E Blethen; Tasneem A Arsiwala; Ross A Fladeland; Samuel A Sprowls; Dhruvi M Panchal; Chris E Adkins; Brooke N Kielkowski; Leland E Earp; Morgan J Glass; Trenton A Pritt; Yssabela M Cabuyao; Sonikpreet Aulakh; Paul R Lockman Journal: Neurooncol Adv Date: 2021-11-27